申请人:Shapiro Gideon
公开号:US20180030055A1
公开(公告)日:2018-02-01
Disclosed are chemical entities of Formula (I): wherein X, Y, Z, R
1
, R
3
, R
4
and R
5
are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).